neurodegenerative diseases
NanoSomiX and Beckman Coulter Diagnostics collaborate on blood tests for neurodegenerative diseases
July 30, 2026Beckman Coulter Diagnostics, NanoSomiX, neurodegenerative diseases
NanoSomiX and Beckman Coulter Diagnostics have announced plans to collaborate on the development of next-generation immunoassays for neurodegenerative diseases using …
PLL Therapeutics to present ALS research strategy at Bioshares Biotech Summit
August 7, 2025Medical Communications, Research and Development Bioshares Biotech Summit, Neurology, PLL Therapeutics, amyotrophic lateral sclerosis, neurodegenerative diseases
French biotech, PLL Therapeutics, will present its approach to early detection and treatment of Amyotrophic Lateral Sclerosis (ALS) at the …
Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline
August 6, 2025Mergers and Acquisitions Alzheimer's disease, Corporate, Neurology, Sanofi, Vigil Neuroscience, neurodegenerative diseases
Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology company specialising in neurodegenerative diseases. …
Neurizon confirms positive results for prospective ALS treatment
June 23, 2025Research and Development Neurizon Therapeutics, Neurology, amyotrophic lateral sclerosis, blood-brain barrier, clinical data, neurodegenerative diseases
Neurizon Therapeutics has announced new preclinical data confirming that NUZ-001 and its active metabolite, NUZ-001 Sulfone, effectively cross the blood-brain …
Sanofi to acquire Vigil Neuroscience, adding Alzheimer’s disease candidate to early-stage pipeline
May 23, 2025Mergers and Acquisitions, Research and Development Alzheimer's disease, Neurology, Sanofi, Vigil Neuroscience, neurodegenerative diseases
Sanofi has announced an agreement to acquire Vigil Neuroscience, a biotech company focused on therapies for neurodegenerative diseases. The deal …
Neurizon makes appointments to executive team
April 24, 2025Recruitment, Senior Management Neurizon, Neurology, als, biotech, neurodegenerative diseases
Neurizon Therapeutics, a clinical-stage biotech company focusing on treatments for neurodegenerative diseases, has announced three leadership appointments. These will support …
Sangamo Therapeutics and Genentech team up to develop genomic medicines for neurodegenerative diseases
August 7, 2024Research and Development Genentech, Neurology, Sangamo Therapeutics, genomic medicine, neurodegenerative diseases
Genomic medicine company Sangamo Therapeutics and Genentech have entered into a licensing agreement to develop intravenously administered genomic medicines to …
Elan signs $20m research deal with Proteostasis
May 25, 2011Research and Development Elan, Proteostasis, neurodegenerative diseases
Elan Corporation has signed a deal with US small molecule drug specialist Proteostasis Therapeutics to develop products for conditions such …
Eisai extends neuroscience partnership with UCL
May 25, 2011Research and Development Eisai, UCL, academic alliance, academic research, neurodegenerative diseases
Eisai and University College London are to extend their partnership in neuroscience research. The Japanese company’s Neuroscience Product Creation Unit …
Biogen Idec buys neurodegenerative disease rights
December 21, 2010Research and Development Alzheimer's, Alzheimer's disease, Alzheimer’s, Alzheimer’s disease, Biogen, Biogen IDEC, Neurimmune, Parkinson's disease, Parkinson’s disease, amyotrophic lateral sclerosis, neurodegenerative diseases
Biogen Idec has acquired a subsidiary of Swiss biotech company Neurimmune, and the rights to three pre-clinical immunotherapy drugs. The …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
